semaglutide non responders GLP-1 nonresponders: Up to 1 in 5 people don't lose weight A CELL FREE DNA METHYLATION-BASED

Our philosophy is not about changing who you are or chasing trends

Not in your liver function tests

Glutathione is classified as generally safe for long-term use

While the length of these effects is unclear (Circana, 2025), these consumption changes are likely to have sweeping consequences for each grocery store, restaurant, food manufacturer, retailer, and farmer in the food system

To be considered for tirzepatide treatment, clients should meet the following requirements: A Body Mass Index (BMI) of 30 kg/m or higher, qualifying as obesity, or a BMI of 27 kg/m or higher if accompanied by at least one weight-related health condition, such as Type 2 diabetes, hypertension, dyslipidemia (high cholesterol or triglycerides), obstructive sleep apnea, or nonalcoholic fatty liver disease (NAFLD)

Tirzepatide is a dual-agonist , meaning it works by targeting two hormones: GLP-1: helps regulate appetite, blood sugar, and digestion GIP: supports insulin response and reduces nausea Retatrutide is a triple-agonist , meaning it targets three hormones: GLP-1: helps regulate appetite, blood sugar, and digestion GIP: supports insulin response and reduces nausea Glucagon: affects energy use and fat metabolism Early studies show that retatrutide may be more successful than tirzepatide at managing diabetic kidney disease, as well as for weight control, while tirzepatide may be better at managing blood glucose